Enjoy complimentary customisation on priority with our Enterprise License!
The atopic dermatitis drugs market size is estimated to grow at a CAGR of 9.28% between 2022 and 2027. The market size is forecast to increase by USD 4,720.19 million. The growth of the market depends on several factors, including the high prevalence of atopic dermatitis, the increasing healthcare expenditure, and the strong R&D pipeline.
This atopic dermatitis drugs market report extensively covers market segmentation by route of administration (oral, topical, and injectable), drug class (biologics, PDE4 inhibitors, corticosteroids, and calcineurin inhibitors), and geography (North America, Europe, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.
To learn more about this report, View Report Sample
The high prevalence of atopic dermatitis is notably driving the market growth, although factors such as the loss of patents and patent expiry may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The high prevalence of atopic dermatitis is the key factor driving the growth of the global atopic dermatitis drugs market. The prevalence of atopic dermatitis is high worldwide. Atopic dermatitis can be caused or exacerbated by several factors, including exposure to allergens such as peanuts, pollen, and animal danger. skin irritants such as household cleaners; certain fabrics or soaps; stress, dry skin, and infections. In the United States alone, approximately 18 million people currently have atopic dermatitis. In the United States, an estimated 9 million to 10 million of her children under the age of 18 suffer from atopic dermatitis, about one-third of whom have moderate to severe disease. Such a large patient pool represents a huge opportunity for the growth of the global atopic dermatitis therapeutics market.
A large patient cohort requires multiple visits to a dermatologist and the use of numerous medications to treat atopic dermatitis, thus driving the market growth. Asia also hosts a huge patient population with atopic dermatitis, with China, India, and Japan being the top three revenue contributors to the market in the region. Developing countries, such as India and China, present promising market opportunities due to their large population base. According to The World Bank Group, the population of China was 1.42 billion in 2021, while that of India was 1.41 billion in the same year. Therefore, the high prevalence of atopic dermatitis is expected to drive the growth of the global atopic dermatitis drugs market during the forecast period.
The geopolitical uncertainties are the primary trend shaping the global atopic dermatitis drugs market. Trade policy uncertainty between nations creates an unfavorable environment for suppliers regarding investment decisions and long-term growth strategies. For instance, the pharmaceutical landscape is changing rapidly in China, with the presence of large American pharmaceutical corporations such as Pfizer, which has invested over USD 1.5 billion in the country so far. However, the trade dispute between the United States and China has adversely affected the operations of many such drug makers. This standoff has adversely affected the import of eczema medications from China into the United States.
China responded to the aggressive trade policies of the US by increasing the tariff on the imports of atopic dermatitis drugs from China. The ongoing trade war has become a major concern for manufacturers and suppliers engaged in the trade of raw materials, active pharmaceutical ingredients (API), as well as finished drugs in both countries, as they are being taxed at multiple points in the supply chain, which is adversely affecting their revenues. Such uncertainties triggered by bilateral disagreements may negatively impact the growth of the global atopic dermatitis drugs market during the forecast period.
Loss of patents and patent expiry is a major challenge to the growth of the global atopic dermatitis drugs market. Loss or revocation of patents poses a significant threat to large companies that own their own patents. Ultimately, the loss or expiration of patents tends to flood the market with generic drugs, losing competitive advantage and margins for large companies. Generic medicines are medicines that are similar in quality, dosage form, strength, and potency to branded medicines but are available at a lower price. Due to the low-price availability of these generic drugs, increasing penetration of generic drugs will limit the market growth.
Allegations associated with the infringement of patents and other intellectual property rights by third parties affect the business of a pharmaceutical company. The expiry of the patent on branded atopic dermatitis drugs will result in the proliferation of generic drugs in the market, thus reducing the sales of branded drugs, which can negatively affect the business of prominent vendors. Thus, this will hinder revenue growth prospects in the market in focus during the forecast period.
The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Atopic Dermatitis Drugs Market Customer Landscape
Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AbbVie Inc.: The company offers atopic dermatitis drugs such as RINVOQ. Also, the company conducts research and development, manufacturing, commercialization and sale of innovative medicines and therapies to allocate resources and assess business performance on a global basis to achieve established long-term strategic goals.
The report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:
Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
The market share growth by the oral segment will be significant during the forecast period. Factors such as, the rising number of approvals of various oral drugs for atopic dermatitis and their benefits, such as ease of use, are expected to drive the segment growth, which in turn, is anticipated to propel the growth of the market in focus during the forecast period.
Get a glance at the market contribution of various segments View the PDF Sample
The oral segment was valued at USD 2,267.71 million in 2017 and continued to grow until 2021. Easy-to-use benefits of drugs that are taken via the oral route and the growing popularity of prescription-based drugs, such as oral capsules, are driving the growth of the oral segment during the forecast period. For instance, in January 2022, AbbVie and Pfizer received approval for Upadacitinib and Abrocitinib from the US FDA for the treatment of refractory moderate to severe atopic dermatitis. Such developments are likely to propel the growth of the oral segment during the forecast period.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 36% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. Among all regions, North America accounted for the largest share of the global atopic dermatitis drug market in 2022. This is due to factors such as the high level of awareness of health care, and the presence of an established medical infrastructure in the region. In addition, the market is expected to show promising growth over the forecast period owing to favorable reimbursement policies, a rising number of drug approvals in the US, and rising healthcare costs. For instance, in the US, national healthcare spending grew by 2.7% in 2021 over 2020 and reached USD 4.3 trillion or USD 12,914 per person. Thus, the growing expenditure associated with healthcare is likely to increase the demand for atopic dermatitis drugs among patients in the region.
The outbreak of COVID-19 affected all countries in North America, especially the US, in 2020. However, by the second quarter of 2021, restrictions were mostly relaxed due to the implementation of mass COVID-19 vaccination in various countries, which led to the resumption of approval processes and the manufacturing of vital drugs, including for the treatment of atopic dermatitis. Such factors will increase the market growth during the forecast period.
The atopic dermatitis drugs market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
Technavio categorizes the global atopic dermatitis drugs market as a part of the global pharmaceuticals market within the overall healthcare industry. The parent, the global pharmaceuticals, market covers products and companies engaged in R&D or the production of generic drugs, non-generic drugs, and veterinary drugs. Our market research report has extensively covered external factors influencing the parent market growth during the forecast period.
Atopic Dermatitis Drugs Market Scope |
|
Report Coverage |
Details |
Page number |
162 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 9.28% |
Market growth 2023-2027 |
USD 4,720.19 million |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
8.68 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 36% |
Key countries |
US, Canada, Germany, UK, and China |
Competitive landscape |
Leading vendors, market positioning of vendors, competitive strategies, and industry risks |
Key companies profiled |
AbbVie Inc., Arcutis Biotherapeutics Inc., Asana BioSciences LLC, Astellas Pharma Inc., Bausch Health Co. Inc., Bayer AG, Bristol Myers Squibb Co., Dermavant Sciences Inc., Eli Lilly and Co., Evelo Biosciences Inc., Galderma SA, Incyte Corp., LEO Pharma AS, Maruho Co. Ltd., Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Sanofi SA, Viatris Inc., and BiomX Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Route of Administration
7 Market Segmentation by Drug Class
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.